NewEdge Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

NewEdge Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$42.5K	Sell	972 -11,025	-92%	-$510K	﹤0.01%	2976
2025 Q4	$545K	Buy	11,997 +5,986	+100%	+$265K	﹤0.01%	1907
2025 Q3	$233K	Buy	6,011 +536	+10%	+$19.4K	﹤0.01%	2324
2025 Q2	$185K	Buy	5,475 +5,100	+1,360%	+$161K	﹤0.01%	2245
2025 Q1	$11.9K	Buy	375 +300	+400%	+$11.4K	﹤0.01%	3033
2024 Q4	$2.91K	Hold	75	–	–	﹤0.01%	3379
2024 Q3	$3.38K	Buy	+75	New	+$3.35K	﹤0.01%	3275
2023 Q1	–	Sell	-27	Closed	-$1.37K	–	3715
2022 Q4	$1.37K	Buy	+27	New	+$1.39K	﹤0.01%	2942

Other funds holding GNOM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $8.76B AUM 23.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

USCWA

U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Armis Advisers Atlanta, Georgia $1.09B AUM 22.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CFD

Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

NewEdge Advisors's GNOM Position: Q1 2026 in Review

NewEdge Advisors reduced its Global X Genomics & Biotechnology ETF (GNOM) stake by 92% in Q1 2026, selling an estimated $510K and leaving 972 shares worth $42.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2976.

NewEdge Advisors first reported a position in GNOM in Q4 2022 and has held it in 8 quarters since. The position peaked at $545K in Q4 2025. 40 funds tracked by Wall St. Rank hold GNOM as of Q1 2026.

NewEdge Advisors held 972 shares of Global X Genomics & Biotechnology ETF worth $42.5K as of Q1 2026.
NewEdge Advisors sold 11,025 Global X Genomics & Biotechnology ETF shares in Q1 2026, an estimated $510K.
Global X Genomics & Biotechnology ETF made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #2976 holding.
NewEdge Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q4 2022 and has held it in 8 quarters since.
NewEdge Advisors's Global X Genomics & Biotechnology ETF position peaked at $545K in Q4 2025.
40 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.